 |
|
|
|
|
|
|
|
 |
Results for 'Combination Therapies' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
CNS Drug Discoveries: Multiple Sclerosis
|
November 2006 |
£795 |
36 % |
Textbook of Interventional Cardiovascular Pharmacology
|
April 2007 |
£140 |
36 % |
Breast Cancer Drug Discoveries
What the future holds 2008
|
December 2008 |
£795 |
35 % |
Launching Combination Products
Brand Extension and Franchise Development Strategies
|
January 2008 |
£1995 |
35 % |
Treating Depression Effectively: Applying Clinical Guidelines
2nd edition
|
August 2007 |
£35 |
30.1 % |
Nutraceuticals
|
April 2007 |
£39.95 |
28 % |
Pharmaceutical Product Relaunch
Preserving Market Share through Line Extension and New Market Entry Strategies
|
April 2007 |
£5265 |
25.9 % |
Stakeholder Perspectives: Pulmonary Arterial Hypertension
A small market gets big attention
|
February 2006 |
£4350 |
25.55 % |
Cancer Therapeutics Markets
|
May 2008 |
£2325 |
24.5 % |
Commercial Insight: Osteoporosis
Risk management and reformulation offer best defense against generic onslaught
|
June 2007 |
£7600 |
24 % |
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
|
July 2007 |
£7600 |
23.5 % |
Crisis Management And Corporate Reputation
Counter-Generics Strategy, Tactics and Execution
|
November 2007 |
£4785 |
21.35 % |
Corporate Security
Protecting Productivity
|
December 2007 |
£4785 |
21.35 % |
Combating Generics 2008
Counter-Generics Strategy, Tactics and Execution
|
December 2007 |
£5265 |
21.35 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£3150 |
20.5 % |
Reformulation Strategies
Comparisons of Past and Future Reformulation Strategies
|
September 2006 |
£4000 |
19.5 % |
Stakeholder Insight: COPD - Another Reason to Quit
|
December 2005 |
£8695 |
19.25 % |
Diabetes Drug Discoveries
What the Future Holds
|
January 2007 |
£1495 |
19 % |
Obesity Drug Discoveries: what the future holds
|
August 2007 |
£1425 |
18.5 % |
World Asthma and COPD Treatment Market, 2006-2011, The
A Changing Market with Increasing Potential
|
September 2006 |
£1499 |
18.2 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
18.2 % |
Pipeline Insight: HIV
Extending treatment options
|
September 2006 |
£6000 |
18 % |
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The
|
January 2007 |
£1540 |
17.85 % |
Cancer Therapeutics
Market Insight and R&D Pipeline Analysis
|
August 2008 |
£2395 |
17.5 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
16.8 % |
Women's Reproductive Disorders Therapeutics 2008-2018
|
September 2008 |
£1499 |
16.8 % |
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments
World Market
|
May 2007 |
£1365 |
16.5 % |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1780 |
16.5 % |
The Dermatology Market Outlook to 2011
|
March 2007 |
£1495 |
16 % |
Urinary Tract Agents Report 2005
|
April 2005 |
£1499 |
15.75 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£4720 |
15.5 % |
Financial Markets Research: ASCO Review Part II
A summary of highlights presented at the ASCO 2006 Annual Meeting
|
August 2006 |
£2195 |
15.05 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
15.05 % |
The Global Antivirals Market
R&D Pipelines, Market Analysis and Competitive Landscape
|
May 2007 |
£1710 |
15.05 % |
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
|
June 2006 |
£1495 |
15.05 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£3150 |
15 % |
Cancer Drug Resistance
2008
|
September 2008 |
£1675 |
14.5 % |
Global Diabetes Market; The
Therapeutics, Diagnostics and Complications
|
August 2006 |
£1710 |
14.35 % |
Commercial and Pipeline Insight: Hepatitis B
|
October 2007 |
£7600 |
14.35 % |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
|
December 2006 |
£2005 |
14 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
13.65 % |
Drug-Device Combinations
|
June 2005 |
£3320 |
13.65 % |
The Cardiovascular Disorders Market Outlook to 2012
|
February 2008 |
£1995 |
13.65 % |
Stakeholder Insight: Respiratory Tract Infections in the USA
The demise of narrow-spectrum antibiotics
|
November 2006 |
£8000 |
12.95 % |
Stakeholder Insight: Respiratory Tract Infections in the USA
The demise of narrow-spectrum antibiotics
|
November 2006 |
£8000 |
12.95 % |
Stakeholder Opinion: Atopic Dermatitis
A high level of unmet need creates market opportunities
|
March 2007 |
£2005 |
12.6 % |
Stakeholder Insight
Asthma - over-Prescribing Is Common in Intermittent and Mild Forms of Asthma
|
July 2008 |
£7600 |
12.6 % |
The Global HIV/Aids Market Outlook To 2012
|
July 2007 |
£1495 |
12.5 % |
Kinetic Concepts Medical Device Company Intelligence Report
|
May 2008 |
£395 |
12.5 % |
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
August 2006 |
£1780 |
12.25 % |
Autoimmune Market Outlook to 2012
|
August 2007 |
£1495 |
12.25 % |
Therapeutic Monoclonal Antibodies Report 2008-2023
|
July 2008 |
£1499 |
12.25 % |
What's Hot in Cancer Drug R&D?
|
July 2006 |
£295 |
12.25 % |
Stakeholder Opinions: Asthma Phenotypes A changing paradigm
|
March 2007 |
£2005 |
11.9 % |
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs
|
May 2007 |
£995 |
11.55 % |
Pipeline Insight: Antiarrhythmics
RSD1235 in a class of its own
|
May 2006 |
£6495 |
11.55 % |
Anti Addiction Therapies, 2006-2011- The Pharmaceutical Industry's Next Viagra?
|
October 2006 |
£1499 |
11.5 % |
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies
|
July 2007 |
£945 |
11.5 % |
Global Antivirals Market Analysis & Forecasts 2008-2023
|
September 2008 |
£1499 |
11.2 % |
Cancer Cell Therapy Markets
|
March 2008 |
£2325 |
11.2 % |
Immunomodulators
Therapeutic Needs, Pipelines & Prospects
|
August 2007 |
£1495 |
11.2 % |
Global Ophthalmic Market Analysis & Forecasts to 2012
|
April 2007 |
£1499 |
10.85 % |
Product Lifecycle Management, 2006
|
May 2006 |
£1499 |
10.85 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£3150 |
10.5 % |
The World Market for Gynaecology
2007-2017
|
September 2007 |
£3200 |
10.5 % |
Drug Delivery Series I-IV
|
April 2007 |
£4890 |
10.15 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
December 2008 |
£2055 |
10.15 % |
The Dermatology Market Outlook to 2013
Competitive Landscape, Pipeline Analysis and Growth Opportunities
|
October 2008 |
£2025 |
10.15 % |
Diagnostics and Therapeutics for Genetic Diseases
|
April 2006 |
£3320 |
10.15 % |
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
|
July 2007 |
£6000 |
9.8 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
9.8 % |
Commercial Insight: Migraine
Opportunities Will Exist In The Wake Of Generic Attack
|
September 2007 |
£7600 |
9.8 % |
Stakeholder Opinions: Fibromyalgia - Potentially lucrative market soon to become reality
|
May 2007 |
£2005 |
9.8 % |
World Allergy Market 2006-2011, The
The Rx-OTC Rush
|
October 2006 |
£1499 |
9.8 % |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
|
October 2006 |
£8000 |
9.45 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
December 2008 |
£1915 |
9.45 % |
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth
|
October 2008 |
£8000 |
9.45 % |
Commercial Insight: Antidyslipidemics
Branded statins beware, generics are amongst you
|
July 2006 |
£8440 |
9.45 % |
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
|
June 2007 |
£7600 |
9.1 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
9.1 % |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
9.1 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£3320 |
9.1 % |
Stakeholder Insight: Metabolic Syndrome
Multiple definitions complicate treatment
|
April 2006 |
£8690 |
8.75 % |
Pipeline Insight: Hepatitis C
Protease inhibitors to drive market expansion
|
June 2006 |
£6495 |
8.75 % |
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline
|
May 2008 |
£6000 |
8.75 % |
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome
Reformulations set to drive near-term growth
|
August 2006 |
£8695 |
8.4 % |
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Combination Products Still Have Blockbuster Potential
|
July 2007 |
£7600 |
8.4 % |
Commercial and Pipeline Insight: Opioids
Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market
|
March 2008 |
£7600 |
8.05 % |
Stakeholder Opinions: Bone Metastases
Impending Patent Expiries May Help Make or Break Newer Agents
|
March 2008 |
£2005 |
8.05 % |
Health and Wellness Healthcare Products in Belgium
|
November 2006 |
£650 |
8.05 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£3150 |
8.05 % |
Health and Wellness Healthcare Products in Indonesia
|
November 2006 |
£650 |
8.05 % |
The Future of Monoclonal Antibodies Therapeutics
Innovation in antibody engineering, key growth strategies and forecasts to 2011
|
July 2006 |
£1495 |
8.05 % |
Parkinson's Disease Market analysis and forecasts
2008-2012, 2017 & 2022
|
January 2008 |
£1499 |
7.7 % |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
December 2006 |
£2005 |
7.7 % |
Antiviral Therapeutics
Technologies, Markets and Companies
|
December 2008 |
£1915 |
7.7 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£3320 |
7.7 % |
Pain Therapeutics
Drugs, Markets and Companies
|
December 2008 |
£2055 |
7.7 % |
Pipeline And Commercial Insight: Parkinson's Disease
Market To Grow As First Round Of Lifecycle Management Strategies Succeed
|
September 2007 |
£7600 |
7.7 % |
Pipeline Insight: Osteoarthritis
The Wait for a DMOAD Continues
|
November 2006 |
£6000 |
7.7 % |
Facial Rejuvenation Markets Worldwide
|
August 2008 |
£1360 |
7.35 % |
Women's Health
Worldwide Prescription Drug Markets
|
August 2006 |
£2670 |
7.35 % |
Women's Health
Worldwide Prescription Drug Markets
|
August 2006 |
£1350 |
7.35 % |
The Global Market for Advanced Wound Care Products 2007
|
March 2007 |
£695 |
7.35 % |
Stakeholder Opinions: Acute Leukemias
Persistent unmet needs confer significant commercial opportunity
|
April 2006 |
£2170 |
7 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£6340 |
7 % |
Oncology Market Leaders
Analyses and Outlook, Market Report 2008 - 2023
|
October 2008 |
£1499 |
7 % |
Pharmacogenomics: New Technologies
In the Development of Personalized Therapies
|
August 2005 |
£3320 |
6.65 % |
Alzheimer's disease
New drugs, markets and companies
|
December 2008 |
£1915 |
6.3 % |
The CNS Market Outlook to 2013
Competitive landscape, pipeline analysis and growth opportunities
|
September 2008 |
£1995 |
6.3 % |
RNAi
Technologies, Markets and Companies
|
December 2008 |
£2055 |
6.3 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£4720 |
6.3 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
6.3 % |
New Dynamics and Challenges in The Generics Market 2007
|
January 2007 |
£1870 |
6 % |
Proteomics
Technologies, Markets and Companies
|
December 2008 |
£2395 |
5.95 % |
Personalized Medicine
scientific & commercial aspects
|
December 2008 |
£2735 |
5.95 % |
Pipeline/Commercial Insight: Supportive Care in Oncology
Significant growth opportunities exist in new supportive care indications
|
June 2007 |
£7600 |
5.6 % |
Global Market for Advanced Wound Care Products 2008, The
A complete review of this fast growing, highly innovative sector
|
April 2008 |
£695 |
5.6 % |
Pipeline Insight: Anxiety Disorders
A decade of declining revenues
|
March 2006 |
£6495 |
5.25 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4515 |
5.25 % |
Cell Therapy
Technologies, Markets and Companies
|
December 2008 |
£3080 |
4.9 % |
Enzyme Inhibitors with Broad Therapeutic Applications
|
June 2006 |
£3320 |
4.9 % |
Commercial Insight: Select Herpes Viruses and Human Papilloma Virus
Non-Biologic Interventions for Oral and Genital Herpes, Cytomegalovirus Infection, Herpes Zoster and Genital Warts
|
August 2008 |
£7600 |
4.55 % |
Global Generics Guide: Part 2
Benchmarking country markets and strategic issue
|
June 2006 |
£8695 |
4.55 % |
Molecular Diagnostics
Technologies, Markets and Companies
|
December 2008 |
£3080 |
3.5 % |
In-Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
2.8 % |
In Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
2.8 % |
|
|
|
|
